This result suggests that the efficacy of FGFR2 inhibitors may be higher in earlier lines of systemic treatment for advanced cholangiocarcinoma; ergo, studies evaluating these drugs on first-line setting might demonstrate higher benefit of these drugs (24). This evidence concerns the gene FGFR2 and cholangiocarcinoma.